Dimensional Fund Advisors LP boosted its holdings in shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Get Rating) by 31.3% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 1,047,533 shares of the company’s stock after buying an additional 249,777 shares during the period. Dimensional Fund Advisors LP’s holdings in Deciphera Pharmaceuticals were worth $19,379,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently made changes to their positions in DCPH. Great West Life Assurance Co. Can acquired a new position in shares of Deciphera Pharmaceuticals during the 3rd quarter valued at about $43,000. US Bancorp DE grew its holdings in Deciphera Pharmaceuticals by 100.6% during the second quarter. US Bancorp DE now owns 4,052 shares of the company’s stock valued at $53,000 after purchasing an additional 2,032 shares during the last quarter. Lazard Asset Management LLC bought a new position in shares of Deciphera Pharmaceuticals in the first quarter valued at approximately $57,000. TD Asset Management Inc. acquired a new stake in shares of Deciphera Pharmaceuticals in the second quarter worth $134,000. Finally, Principal Financial Group Inc. bought a new stake in shares of Deciphera Pharmaceuticals during the 2nd quarter worth $134,000. Institutional investors and hedge funds own 72.66% of the company’s stock.
Analyst Upgrades and Downgrades
Several research analysts recently commented on DCPH shares. Guggenheim upgraded shares of Deciphera Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $22.00 target price on the stock in a report on Wednesday, January 4th. Barclays lifted their price objective on Deciphera Pharmaceuticals from $8.00 to $9.00 and gave the stock an “underweight” rating in a research note on Wednesday, January 4th. SVB Leerink raised their target price on Deciphera Pharmaceuticals from $28.00 to $30.00 and gave the company an “outperform” rating in a report on Tuesday, February 7th. HC Wainwright reiterated a “buy” rating and set a $25.00 price target on shares of Deciphera Pharmaceuticals in a report on Wednesday, February 8th. Finally, Jonestrading raised Deciphera Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, January 6th. One analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $22.22.
Deciphera Pharmaceuticals Trading Up 0.2 %
Deciphera Pharmaceuticals (NASDAQ:DCPH – Get Rating) last announced its quarterly earnings results on Tuesday, February 7th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.03). The business had revenue of $36.40 million during the quarter, compared to the consensus estimate of $35.88 million. Deciphera Pharmaceuticals had a negative net margin of 133.49% and a negative return on equity of 51.42%. The company’s quarterly revenue was up 50.4% compared to the same quarter last year. During the same period last year, the firm earned ($1.51) EPS. Equities analysts forecast that Deciphera Pharmaceuticals, Inc. will post -2.35 earnings per share for the current fiscal year.
Insider Activity at Deciphera Pharmaceuticals
In related news, major shareholder Brightstar Associates Llc acquired 1,666,666 shares of the firm’s stock in a transaction on Tuesday, January 24th. The shares were bought at an average cost of $18.00 per share, with a total value of $29,999,988.00. Following the completion of the acquisition, the insider now owns 19,718,014 shares of the company’s stock, valued at $354,924,252. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, major shareholder Brightstar Associates Llc acquired 1,666,666 shares of the business’s stock in a transaction on Tuesday, January 24th. The stock was bought at an average cost of $18.00 per share, with a total value of $29,999,988.00. Following the completion of the acquisition, the insider now owns 19,718,014 shares in the company, valued at $354,924,252. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Daniel Lee Flynn sold 2,403 shares of the company’s stock in a transaction dated Tuesday, January 17th. The stock was sold at an average price of $21.24, for a total transaction of $51,039.72. Following the completion of the sale, the insider now directly owns 43,695 shares in the company, valued at approximately $928,081.80. The disclosure for this sale can be found here. Insiders have sold a total of 5,903 shares of company stock valued at $103,890 over the last quarter. 4.30% of the stock is owned by company insiders.
Deciphera Pharmaceuticals Profile
Deciphera Pharmaceuticals, Inc is a biopharmaceutical company, which engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The firm designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors.
- Get a free copy of the StockNews.com research report on Deciphera Pharmaceuticals (DCPH)
- Go Where the Money Is. Here’s 3 Top Bank Dividend Stocks to Buy
- Another Catalyst For Mullen Automotive Stock
- Solar Tech-Services; Nextracker Should Be On Your Radar
- Is American Lithium a Safe Bet as Demand for Lithium Soars
- Highwoods Properties, High-quality Real Estate for a Discount
Want to see what other hedge funds are holding DCPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Get Rating).
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.